Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...
Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone ...
Eli Lilly and Company announced results from the primary overall survival (OS) analysis of the phase 3 monarchE trial showing that two years of adjuvant Verzenio plus endocrine therapy (ET) reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback